Tekla Life Sciences Inves... (HQL)
NYSE: HQL
· Real-Time Price · USD
16.46
0.25 (1.54%)
At close: Oct 15, 2025, 3:59 PM
16.45
-0.06%
After-hours: Oct 15, 2025, 06:21 PM EDT
Tekla Life Sciences Investors Cash Flow Statement
Financials in USD. Fiscal
year is
October - September.
| Fiscal Year | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 | Q2 2021 |
| Period Ending | Mar 31, 2025 | Sep 30, 2024 | Mar 31, 2024 | Sep 30, 2023 | Mar 31, 2023 | Sep 30, 2022 | Mar 31, 2022 | Sep 30, 2021 | Mar 31, 2021 |
Net Income | -47.23M | n/a | 11.18M | 44.98M | 33.75M | -104.6K | -20.04K | 64.53K | 93.79K |
Depreciation & Amortization | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Stock-Based Compensation | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | -73.8K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Accounts Receivables | -123.27K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Inventory | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Accounts Payables | -15.28K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Working Capital | 64.75K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Non-Cash Items | 46.26M | n/a | -11.18M | -44.98M | -33.75M | 104.6K | 20.04K | -64.53K | -93.79K |
Net Cash from Operating Activities | -1.04M | n/a | n/a | n/a | n/a | n/a | -0.37 | -0.74 | -0.37 |
Operating Cash Flow | -1.04M | n/a | n/a | n/a | n/a | n/a | -0.37 | -0.74 | -0.37 |
PP&E Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Capital Expenditures | -4 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | -157.46M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities of Investments | 161.84M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Activities | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Net Cash from Investing Activities | 4.39M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Net Debt Issuance | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Long-Term Net Debt Issuance | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Short-Term Net Debt Issuance | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Net Stock Issuance | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Net Common Stock Issuance | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Issuance | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Net Preferred Stock Issuance | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Net Dividends Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Dividends Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Preferred Dividends Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financing Activities | -8.41M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Net Cash from Financing Activities | -8.41M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Effect of Forex Changes on Cash | 5.07M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Net Change in Cash | n/a | n/a | 32.00 | 32.00 | -545 | -1.09K | -545.74 | -1.49 | -0.74 |
Cash at End of Period | n/a | n/a | n/a | 477.00 | n/a | 445.00 | 445.00 | -0.74 | -0.74 |
Cash at Beginning of Period | n/a | n/a | 445.00 | n/a | 990.00 | 990.00 | n/a | n/a | 1.12M |
Free Cash Flow | -1.04M | n/a | n/a | n/a | n/a | n/a | -0.37 | -0.74 | -0.37 |
Income Taxes Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Interest Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Source: Financial Modeling Prep. Financial Sources.